Copyright © 2000 by the European Society of Cardiology.
White coat effect, blood pressure and mortality in men: prospective cohort study
Department of Medicine, University of Helsinki and National Public Health Institute, Helsinki, Finland
revised November 23, 1999; accepted December 1, 1999
Abstract
Background Because long-term follow-up studies, which also included normotensive controls, have been lacking, the clinical significance of ‘white coat’ effect and of ‘white coat’ hypertension has remained controversial.
Methods and Results Twenty-one-year prospective data was gathered in 536 men with cardiovascular risk factors at baseline. Blood pressure was measured both by a nurse and by a physician and ‘white coat effect’ was defined as the difference between the two measurements (physician minus nurse). In addition, four blood pressure groups were categorized: normotensive (n=259), white coat hypertensive (n=18), mildly hypertensive (n=150) and persistently hypertensive (n=109). Comparison of these groups at baseline showed that men with white coat hypertension had higher levels of metabolic risk factors. Sixty-eight men died during follow-up. The men with a white coat effect >30mmHg (n=37) had significantly higher mortality than other men (relative risk 2·2, 95% confidence interval 1·1–4·2). Mortality was significantly higher in the white coat hypertensive group (33·3%) than in the normotensive group (9·5%, P=0·0005 between groups). Relative risk adjusted for baseline risk factors in the white coat hypertensive group was 3·3 (1·2–7·6) compared with the normotensive group. The development of drug-treated hypertension was also more common (27·8% vs 13·4% in the normotensive group, P<0·0001 between groups).
Conclusion The results suggest that white coat hypertension or a large white coat effect is not an innocent phenomenon. It tends to co-exist with metabolic risk factors and predicts total and cardiovascular mortality during long-term follow-up.
Key Words: White coat, hypertension, blood pressure, mortality
f1 Correspondence: Timo E. Strandberg, MD, P.O. Box 340, FIN-00029 HYKS, Finland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Pyhala, K. Raikkonen, K. Feldt, S. Andersson, P. Hovi, J. G. Eriksson, A.-L. Jarvenpaa, and E. Kajantie Blood Pressure Responses to Psychosocial Stress in Young Adults With Very Low Birth Weight: Helsinki Study of Very Low Birth Weight Adults Pediatrics, February 1, 2009; 123(2): 731 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Dawes, G. Bartlett, A. J. Coats, and E. Juszczak Comparing the Effects of White Coat Hypertension and Sustained Hypertension on Mortality in a UK Primary Care Setting Ann. Fam. Med, September 1, 2008; 6(5): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grassi, G. Seravalle, F. Q. Trevano, R. Dell'Oro, G. Bolla, C. Cuspidi, F. Arenare, and G. Mancia Neurogenic Abnormalities in Masked Hypertension Hypertension, September 1, 2007; 50(3): 537 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mancia, R. Facchetti, M. Bombelli, G. Grassi, and R. Sega Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure Hypertension, May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Messerli and D. Cotiga Masked Hypertension and White-Coat Hypertension: Therapeutic Navigation Between Scylla and Charybdis J. Am. Coll. Cardiol., August 2, 2005; 46(3): 516 - 517. [Full Text] [PDF]
|
|
|
|
|
|
J. Gomez-Cerezo, J. J. Rios Blanco, I. Suarez Garcia, P. Moreno Anaya, P. Garcia Raya, E. Vazquez-Munoz, and F. J. Barbado Hernandez Noninvasive Study of Endothelial Function in White Coat Hypertension Hypertension, September 1, 2002; 40(3): 304 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verdecchia, J.A. Staessen, W.B. White, Y. Imai, and E.T. O'Brien Properly defining white coat hypertension Eur. Heart J., January 2, 2002; 23(2): 106 - 109. [Full Text] [PDF]
|
|